Advances in Biomarkers of Major Depressive Disorder

Advances in Clinical Chemistry

Volumn 68, Issue , 2015, Pages 177-204

  Huang, Tiao Lai ^a   Lin, Chin Chuen ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Brain derived neurotrophic factor; Epigenetics; Immune; Inflammation; Interactomics; Major depressive disorder; Metabolomics; Pharmacogenetics; Proteomics

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; CATECHOL METHYLTRANSFERASE; CYTOKINE; LIPID; SEROTONIN TRANSPORTER;

BLOOD; DEPRESSIVE DISORDER, MAJOR; DIAGNOSIS; GENETICS; HUMAN; METABOLOMICS; SINGLE NUCLEOTIDE POLYMORPHISM;

BIOLOGICAL MARKERS; BLOOD; BRAIN-DERIVED NEUROTROPHIC FACTOR; CATECHOL O-METHYLTRANSFERASE; CYTOKINES; DEPRESSIVE DISORDER, MAJOR; DIAGNOSIS; GENETICS; HUMANS; LIPIDS; METABOLOMICS; MONOAMINE OXIDASE; POLYMORPHISM, SINGLE NUCLEOTIDE; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 84964273561     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/bs.acc.2014.11.003     Document Type: Chapter

References (171)

1. Pyne J.M., Patterson T.L., Kaplan R.M., Ho S., Gillin J.C., Golshan S., et al. Preliminary longitudinal assessment of quality of life in patients with major depression. Psychopharmacol. Bull. 1997, 33(1):23-29.
2. Biomarkers Definitions Working Group Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 2001, 69(3):89-95.
3. Boksa P. A way forward for research on biomarkers for psychiatric disorders. J. Psychiatry Neurosci. 2013, 38(2):75-77.
4. Kluge W., Alsaif M., Guest P.C., Schwarz E., Bahn S. Translating potential biomarker candidates for schizophrenia and depression to animal models of psychiatric disorders. Expert. Rev. Mol. Diagn. 2011, 11(7):721-733.
5. Schmidt H.D., Shelton R.C., Duman R.S. Functional biomarkers of depression: diagnosis, treatment, and pathophysiology. Neuropsychopharmacology 2011, 36(12):2375-2394.
6. Murrough J.W., Charney D.S. Is there anything really novel on the antidepressant horizon?. Curr. Psychiatry Rep. 2012, 14(6):643-649.
7. DiMatteo M.R., Lepper H.S., Croghan T.W. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch. Intern. Med. 2000, 160(14):2101-2107.
8. Muldoon M.F., Manuck S.B., Matthews K.A. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. Br. Med. J. 1990, 301(6747):309-314.
9. Glueck C.J., Tieger M., Kunkel R., Hamer T., Tracy T., Speirs J. Hypocholesterolemia and affective disorders. Am. J. Med. Sci. 1994, 308(4):218-225.
10. Olusi S.O., Fido A.A. Serum lipid concentrations in patients with major depressive disorder. Biol. Psychiatry 1996, 40(11):1128-1131.
11. Partonen T., Haukka J., Virtamo J., Taylor P.R., Lonnqvist J. Association of low serum total cholesterol with major depression and suicide. Br. J. Psychiatry 1999, 175:259-262.
12. Wallner B., Machatschke I.H. The evolution of violence in men: the function of central cholesterol and serotonin. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33(3):391-397.
13. Chen C.C., Lu F.H., Wu J.S., Chang C.J. Correlation between serum lipid concentrations and psychological distress. Psychiatry Res. 2001, 102(2):153-162.
14. Maes M., Smith R., Christophe A., Vandoolaeghe E., Van Gastel A., Neels H., et al. Lower serum high-density lipoprotein cholesterol (HDL-C) in major depression and in depressed men with serious suicidal attempts: relationship with immune-inflammatory markers. Acta Psychiatr. Scand. 1997, 95(3):212-221.
15. Huang T.L. Serum cholesterol levels in mood disorders associated with physical violence or suicide attempts in Taiwanese. Chang Gung Med. J. 2001, 24(9):563-568.
16. Huang T.L., Wu S.C., Chiang Y.S., Chen J.F. Correlation between serum lipid, lipoprotein concentrations and anxious state, depressive state or major depressive disorder. Psychiatry Res. 2003, 118(2):147-153.
17. Huang T.L., Chen J.F. Lipid and lipoprotein levels in depressive disorders with melancholic feature or atypical feature and dysthymia. Psychiatry Clin. Neurosci. 2004, 58(3):295-299.
18. Huang T.L. Serum lipid profiles in major depression with clinical subtypes, suicide attempts and episodes. J. Affect. Disord. 2005, 86(1):75-79.
19. Huang T.L., Chen J.F. Cholesterol and lipids in depression: stress, hypothalamo-pituitary-adrenocortical axis, and inflammation/immunit. Adv. Clin. Chem. 2005, 39:81-105.
20. Maes M., Delange J., Ranjan R., Meltzer H.Y., Desnyder R., Cooremans W., et al. Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs. Psychiatry Res. 1997, 66(1):1-11.
21. Song C., Dinan T., Leonard B.E. Changes in immunoglobulin, complement and acute phase protein levels in the depressed patients and normal controls. J. Affect. Disord. 1994, 30(4):283-288.
22. Maes M., Bosmans E., Suy E., Vandervorst C., DeJonckheere C., Raus J. Depression-related disturbances in mitogen-induced lymphocyte responses and interleukin-1 beta and soluble interleukin-2 receptor production. Acta Psychiatr. Scand. 1991, 84(4):379-386.
23. Seidel A., Arolt V., Hunstiger M., Rink L., Behnisch A., Kirchner H. Cytokine production and serum proteins in depression. Scand. J. Immunol. 1995, 41(6):534-538.
24. Chang T.T., Yen Y.C. Cytokines and major psychiatric disorders. Taiwan. J. Psychiatry (Taipei) 2010, 24:257-268.
25. Myint A.M., Leonard B.E., Steinbusch H.W., Kim Y.K. Th1, Th2, and Th3 cytokine alterations in major depression. J. Affect. Disord. 2005, 88(2):167-173.
26. Schiepers O.J.G., Wichers M.C., Maes M. Cytokines and major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 2005, 29(2):201-217.
27. Krishnadas R., Cavanagh J. Depression: an inflammatory illness?. J. Neurol. Neurosurg. Psychiatry 2012, 83(5):495-502.
28. Leonard B.E. The concept of depression as a dysfunction of the immune system. Curr. Immunol. Rev. 2010, 6(3):205-212.
29. Dowlati Y., Herrmann N., Swardfager W., Liu H., Sham L., Reim E.K., et al. A meta-analysis of cytokines in major depression. Biol. Psychiatry 2010, 67(5):446-457.
30. Valkanova V., Ebmeier K.P., Allan C.L. CRP, IL-6 and depression: a systematic review and meta-analysis of longitudinal studies. J. Affect. Disord. 2013, 150(3):736-744.
31. Hannestad J., DellaGioia N., Bloch M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology 2011, 36(12):2452-2459.
32. Huang T.L. Lower serum albumin levels in patients with mood disorders. Chang Gung Med. J. 2002, 25(8):509-513.
33. Huang T.L., Lee C.T. Low serum albumin and high ferritin levels in chronic hemodialysis patients with major depression. Psychiatry Res. 2007, 152(2-3):277-280.
34. Huang T.L., Lee C.T. T-helper 1/T-helper 2 cytokine imbalance and clinical phenotypes of acute-phase major depression. Psychiatry Clin. Neurosci. 2007, 61(4):415-420.
35. Huang T.L., Lin F.C. High-sensitivity C-reactive protein levels in patients with major depressive disorder and bipolar mania. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31(2):370-372.
36. Brunoni A.R., Lopes M., Fregni F. A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int. J. Neuropsychopharmacol. 2008, 11(8):1169-1180.
37. Krishnan V., Nestler E.J. The molecular neurobiology of depression. Nature 2008, 455(7215):894-902.
38. Dwivedi Y. Brain-derived neurotrophic factor: role in depression and suicide. Neuropsychiatr. Dis. Treat. 2009, 5:433-449.
39. Kang H.J., Kim J.M., Lee J.Y., Kim S.Y., Bae K.Y., Kim S.W., et al. BDNF promoter methylation and suicidal behavior in depressive patients. J. Affect. Disord. 2013, 151(2):679-685.
40. Duman R.S., Heninger G.R., Nestler E.J. A molecular and cellular theory of depression. Arch. Gen. Psychiatry 1997, 54(7):597-606.
41. Altar C.A. Neurotrophins and depression. Trends Pharmacol. Sci. 1999, 20(2):59-61.
42. Nestler E.J., Barrot M., DiLeone R.J., Eisch A.J., Gold S.J., Monteggia L.M. Neurobiology of depression. Neuron 2002, 34(1):13-25.
43. Dwivedi Y., Rizavi H.S., Conley R.R., Roberts R.C., Tamminga C.A., Pandey G.N. Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects. Arch. Gen. Psychiatry 2003, 60(8):804-815.
44. Gonul A.S., Akdeniz F., Taneli F., Donat O., Eker C., Vahip S. Effect of treatment on serum brain-derived neurotrophic factor levels in depressed patients. Eur. Arch. Psychiatry Clin. Neurosci. 2005, 255(6):381-386.
45. Karege F., Bondolfi G., Gervasoni N., Schwald M., Aubry J.M., Bertschy G. Low brain-derived neurotrophic factor (BDNF) levels in serum of depressed patients probably results from lowered platelet BDNF release unrelated to platelet reactivity. Biol. Psychiatry 2005, 57(9):1068-1072.
46. Huang T.L., Lee C.T., Liu Y.L. Serum brain-derived neurotrophic factor levels in patients with major depression: effects of antidepressants. J. Psychiatr. Res. 2008, 42(7):521-525.
47. Hung Y.Y., Lin C.J., Huang T.L. Higher serum tropomyosin-related kinase B protein level in major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 2010, 34(4):610-612.
48. Lin C.C., Huang T.L. Increased serum tropomyosin-related kinase B protein level in obese patients with major depressive disorder. Taiwan. J. Psychiatry 2010, 24(4):301-306.
49. Lesch K.P., Meyer J., Glatz K., Flugge G., Hinney A., Hebebrand J., et al. The 5-HT transporter gene-linked polymorphic region (5-HTTLPR) in evolutionary perspective: alternative biallelic variation in rhesus monkeys. Rapid communication. J. Neural Transm. 1997, 104(11-12):1259-1266.
50. Smeraldi E., Zanardi R., Benedetti F., Di Bella D., Perez J., Catalano M. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol. Psychiatry 1998, 3(6):508-511.
51. Goldman N., Glei D.A., Lin Y.H., Weinstein M. The serotonin transporter polymorphism (5-HTTLPR): allelic variation and links with depressive symptoms. Depress. Anxiety 2010, 27(3):260-269.
52. Kunugi H., Hattori M., Kato T., Tatsumi M., Sakai T., Sasaki T., et al. Serotonin transporter gene polymorphisms: ethnic difference and possible association with bipolar affective disorder. Mol. Psychiatry 1997, 2(6):457-462.
53. Mrazek D.A., Rush A.J., Biernacka J.M., O'Kane D.J., Cunningham J.M., Wieben E.D., et al. SLC6A4 variation and citalopram response. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2009, 150B(3):341-351.
54. Porcelli S., Fabbri C., Serretti A. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. Eur. Neuropsychopharmacol. 2012, 22(4):239-258.
55. Bousman C.A., Sarris J., Won E.S., Chang H.S., Singh A., Lee H.Y., et al. Escitalopram efficacy in depression: a cross-ethnicity examination of the serotonin transporter promoter polymorphism. J. Clin. Psychopharmacol. 2014, 34(5):645-648.
56. Ng C., Sarris J., Singh A., Bousman C., Byron K., Peh L.H., et al. Pharmacogenetic polymorphisms and response to escitalopram and venlafaxine over 8 weeks in major depression. Hum. Psychopharmacol. 2013, 28(5):516-522.
57. Myung W., Lim S.W., Kim S., Kim H., Chung J.W., Seo M.Y., et al. Serotonin transporter genotype and function in relation to antidepressant response in Koreans. Psychopharmacology (Berl.) 2013, 225(2):283-290.
58. Won E.S., Chang H.S., Lee H.Y., Ham B.J., Lee M.S. Association between serotonin transporter-linked polymorphic region and escitalopram antidepressant treatment response in Korean patients with major depressive disorder. Neuropsychobiology 2012, 66(4):221-229.
59. Zhao J., Goldberg J., Bremner J.D., Vaccarino V. Association between promoter methylation of serotonin transporter gene and depressive symptoms: a monozygotic twin study. Psychosom. Med. 2013, 75(6):523-529.
60. Okada S., Morinobu S., Fuchikami M., Segawa M., Yokomaku K., Kataoka T., et al. The potential of SLC6A4 gene methylation analysis for the diagnosis and treatment of major depression. J. Psychiatr. Res. 2014, 53:47-53.
61. Domschke K., Tidow N., Schwarte K., Deckert J., Lesch K.P., Arolt V., et al. Serotonin transporter gene hypomethylation predicts impaired antidepressant treatment response. Int. J. Neuropsychopharmacol. 2014, 17(8):1167-1176.
62. McMahon F.J., Buervenich S., Charney D., Lipsky R., Rush A.J., Wilson A.F., et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am. J. Hum. Genet. 2006, 78(5):804-814.
63. Lucae S., Ising M., Horstmann S., Baune B.T., Arolt V., Muller-Myhsok B., et al. HTR2A gene variation is involved in antidepressant treatment response. Eur. Neuropsychopharmacol. 2010, 20(1):65-68.
64. Uher R., Huezo-Diaz P., Perroud N., Smith R., Rietschel M., Mors O., et al. Genetic predictors of response to antidepressants in the GENDEP project. Pharmacogenomics J. 2009, 9(4):225-233.
65. Staeker J., Leucht S., Laika B., Steimer W. Polymorphisms in serotonergic pathways influence the outcome of antidepressant therapy in psychiatric inpatients. Genet. Test. Mol. Biomarkers 2014, 18(1):20-31.
66. Serretti A., Fabbri C., Pellegrini S., Porcelli S., Politi P., Bellino S., et al. No effect of serotoninergic gene variants on response to interpersonal counseling and antidepressants in major depression. Psychiatry Investig. 2013, 10(2):180-189.
67. Arias B., Fabbri C., Gressier F., Serretti A., Mitjans M., Gasto C., et al. TPH1, MAOA, serotonin receptor 2A and 2C genes in citalopram response: possible effect in melancholic and psychotic depression. Neuropsychobiology 2013, 67(1):41-47.
68. Kim Y.G., Chang H.S., Won E.S., Ham B.J., Lee M.S. Serotonin-related polymorphisms in TPH1 and HTR5A genes are not associated with escitalopram treatment response in Korean patients with major depression. Neuropsychobiology 2014, 69(4):210-219.
69. Jin C., Xu W., Yuan J., Wang G., Cheng Z. Meta-analysis of association between the -1438A/G (rs6311) polymorphism of the serotonin 2A receptor gene and major depressive disorder. Neurol. Res. 2013, 35(1):7-14.
70. Serretti A., Zanardi R., Rossini D., Cusin C., Lilli R., Smeraldi E. Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity. Mol. Psychiatry 2001, 6(5):586-592.
71. Serretti A., Zanardi R., Cusin C., Rossini D., Lorenzi C., Smeraldi E. Tryptophan hydroxylase gene associated with paroxetine antidepressant activity. Eur. Neuropsychopharmacol. 2001, 11(5):375-380.
72. Ham B.J., Lee B.C., Paik J.W., Kang R.H., Choi M.J., Choi I.G., et al. Association between the tryptophan hydroxylase-1 gene A218C polymorphism and citalopram antidepressant response in a Korean population. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31(1):104-107.
73. Hong C.J., Chen T.J., Yu Y.W., Tsai S.J. Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder. Pharmacogenomics J. 2006, 6(1):27-33.
74. Peters E.J., Slager S.L., Jenkins G.D., Reinalda M.S., Garriock H.A., Shyn S.I., et al. Resequencing of serotonin-related genes and association of tagging SNPs to citalopram response. Pharmacogenet. Genomics 2009, 19(1):1-10.
75. Andre K., Kampman O., Viikki M., Illi A., Setala-Soikkeli E., Poutanen O., et al. TPH1 A218C polymorphism and temperament in major depression. BMC Psychiatry 2013, 13:118.
76. Peters E.J., Slager S.L., McGrath P.J., Knowles J.A., Hamilton S.P. Investigation of serotonin-related genes in antidepressant response. Mol. Psychiatry 2004, 9(9):879-889.
77. Tzvetkov M.V., Brockmoller J., Roots I., Kirchheiner J. Common genetic variations in human brain-specific tryptophan hydroxylase-2 and response to antidepressant treatment. Pharmacogenet. Genomics 2008, 18(6):495-506.
78. Tsai S.J., Hong C.J., Liou Y.J., Yu Y.W., Chen T.J., Hou S.J., et al. Tryptophan hydroxylase 2 gene is associated with major depression and antidepressant treatment response. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33(4):637-641.
79. Hammer C., Degenhardt F., Priebe L., Stutz A.M., Heilmann S., Waszak S.M., et al. A common microdeletion affecting a hippocampus- and amygdala-specific isoform of tryptophan hydroxylase 2 is not associated with affective disorders. Bipolar Disord. 2014, 16(7):764-768.
80. Nazree N.E., Loke A.C., Zainal N.Z., Mohamed Z. Lack of association between TPH2 gene polymorphisms with major depressive disorder in multiethnic Malaysian population. Asia Pac. Psychiatry 2013, [Epub ahead of print].
81. Rotberg B., Kronenberg S., Carmel M., Frisch A., Brent D., Zalsman G., et al. Additive effects of 5-HTTLPR (serotonin transporter) and tryptophan hydroxylase 2G-703T gene polymorphisms on the clinical response to citalopram among children and adolescents with depression and anxiety disorders. J. Child Adolesc. Psychopharmacol. 2013, 23(2):117-122.
82. Yu Y.W., Tsai S.J., Hong C.J., Chen T.J., Chen M.C., Yang C.W. Association study of a monoamine oxidase A gene promoter polymorphism with major depressive disorder and antidepressant response. Neuropsychopharmacology 2005, 30(9):1719-1723.
83. Domschke K., Hohoff C., Mortensen L.S., Roehrs T., Deckert J., Arolt V., et al. Monoamine oxidase A variant influences antidepressant treatment response in female patients with major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32(1):224-228.
84. Tzeng D.S., Chien C.C., Lung F.W., Yang C.Y. MAOA gene polymorphisms and response to mirtazapine in major depression. Hum. Psychopharmacol. 2009, 24(4):293-300.
85. Serretti A., Zanardi R., Franchini L., Artioli P., Dotoli D., Pirovano A., et al. Pharmacogenetics of selective serotonin reuptake inhibitor response: a 6-month follow-up. Pharmacogenetics 2004, 14(9):607-613.
86. Tadic A., Muller M.J., Rujescu D., Kohnen R., Stassen H.H., Dahmen N., et al. The MAOA T941G polymorphism and short-term treatment response to mirtazapine and paroxetine in major depression. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2007, 144B(3):325-331.
87. Leuchter A.F., McCracken J.T., Hunter A.M., Cook I.A., Alpert J.E. Monoamine oxidase A and catechol-O-methyltransferase functional polymorphisms and the placebo response in major depressive disorder. J. Clin. Psychopharmacol. 2009, 29(4):372-377.
88. Tiwari A.K., Zai C.C., Sajeev G., Arenovich T., Muller D.J., Kennedy J.L. Analysis of 34 candidate genes in bupropion and placebo remission. Int. J. Neuropsychopharmacol. 2013, 16(4):771-781.
89. Domschke K., Tidow N., Schwarte K., Ziegler C., Lesch K.P., Deckert J., et al. Pharmacoepigenetics of depression: no major influence of MAO-A DNA methylation on treatment response. J. Neural Transm. 2014.
90. Szegedi A., Rujescu D., Tadic A., Muller M.J., Kohnen R., Stassen H.H., et al. The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression. Pharmacogenomics J. 2005, 5(1):49-53.
91. Arias B., Serretti A., Lorenzi C., Gasto C., Catalan R., Fananas L. Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European origin. J. Affect. Disord. 2006, 90(2-3):251-256.
92. Spronk D., Arns M., Barnett K.J., Cooper N.J., Gordon E. An investigation of EEG, genetic and cognitive markers of treatment response to antidepressant medication in patients with major depressive disorder: a pilot study. J. Affect. Disord. 2011, 128(1-2):41-48.
93. Benedetti F., Dallaspezia S., Colombo C., Lorenzi C., Pirovano A., Smeraldi E. Effect of catechol-O-methyltransferase Val(108/158)Met polymorphism on antidepressant efficacy of fluvoxamine. Eur. Psychiatry 2010, 25(8):476-478.
94. Kocabas N.A., Faghel C., Barreto M., Kasper S., Linotte S., Mendlewicz J., et al. The impact of catechol-O-methyltransferase SNPs and haplotypes on treatment response phenotypes in major depressive disorder: a case-control association study. Int. Clin. Psychopharmacol. 2010, 25(4):218-227.
95. Houston J.P., Kohler J., Ostbye K.M., Heinloth A., Perlis R.H. Association of catechol-O-methyltransferase variants with duloxetine response in major depressive disorder. Psychiatry Res. 2011, 189(3):475-477.
96. Fukui N., Suzuki Y., Sugai T., Watanabe J., Ono S., Tsuneyama N., et al. Promoter variation in the catechol-O-methyltransferase gene is associated with remission of symptoms during fluvoxamine treatment for major depression. Psychiatry Res. 2014, 218(3):353-355.
97. Shen X., Wu Y., Guan T., Wang X., Qian M., Lin M., et al. Association analysis of COMT/MTHFR polymorphisms and major depressive disorder in Chinese Han population. J. Affect. Disord. 2014, 161:73-78.
98. Chiesa A., Lia L., Alberti S., Lee S.J., Han C., Patkar A.A., et al. Lack of influence of rs4680 (COMT) and rs6276 (DRD2) on diagnosis and clinical outcomes in patients with major depression. Int. J. Psychiatry Clin. Pract. 2014, 18(2):97-102.
99. Xu G., Lin K., Rao D., Dang Y., Ouyang H., Mai G., et al. Brain-derived neurotrophic factor gene polymorphism (Val66Met) and the early response to antidepressant in Chinese Han population. Psychiatr. Genet. 2012, 22(4):214-215.
100. Taylor W.D., McQuoid D.R., Ashley-Koch A., MacFall J.R., Bridgers J., Krishnan R.R., et al. BDNF Val66Met genotype and 6-month remission rates in late-life depression. Pharmacogenomics J. 2011, 11(2):146-154.
101. Katsuki A., Yoshimura R., Kishi T., Hori H., Umene-Nakano W., Ikenouchi-Sugita A., et al. Serum levels of brain-derived neurotrophic factor (BDNF), BDNF gene Val66Met polymorphism, or plasma catecholamine metabolites, and response to mirtazapine in Japanese patients with major depressive disorder (MDD). CNS Spectr. 2012, 17(3):155-163.
102. Kang R.H., Chang H.S., Wong M.L., Choi M.J., Park J.Y., Lee H.Y., et al. Brain-derived neurotrophic factor gene polymorphisms and mirtazapine responses in Koreans with major depression. J. Psychopharmacol. 2010, 24(12):1755-1763.
103. Licinio J., Dong C., Wong M.L. Novel sequence variations in the brain-derived neurotrophic factor gene and association with major depression and antidepressant treatment response. Arch. Gen. Psychiatry 2009, 66(5):488-497.
104. Gratacos M., Soria V., Urretavizcaya M., Gonzalez J.R., Crespo J.M., Bayes M., et al. A brain-derived neurotrophic factor (BDNF) haplotype is associated with antidepressant treatment outcome in mood disorders. Pharmacogenomics J. 2008, 8(2):101-112.
105. Domschke K., Lawford B., Laje G., Berger K., Young R., Morris P., et al. Brain-derived neurotrophic factor (BDNF) gene: no major impact on antidepressant treatment response. Int. J. Neuropsychopharmacol. 2010, 13(1):93-101.
106. Murphy G.M., Sarginson J.E., Ryan H.S., O'Hara R., Schatzberg A.F., Lazzeroni L.C. BDNF and CREB1 genetic variants interact to affect antidepressant treatment outcomes in geriatric depression. Pharmacogenet. Genomics 2013, 23(6):301-313.
107. Hennings J.M., Kohli M.A., Czamara D., Giese M., Eckert A., Wolf C., et al. Possible associations of NTRK2 polymorphisms with antidepressant treatment outcome: findings from an extended tag SNP approach. PLoS One 2013, 8(6):e64947.
108. Illi A., Viikki M., Poutanen O., Setala-Soikkeli E., Nuolivirta T., Kampman O., et al. No support for a role for BDNF gene polymorphisms rs11030101 and rs61888800 in major depressive disorder or antidepressant response in patients of Finnish origin. Psychiatr. Genet. 2013, 23(1):33-35.
109. Berton O., McClung C.A., Dileone R.J., Krishnan V., Renthal W., Russo S.J., et al. Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science 2006, 311(5762):864-868.
110. Tsankova N.M., Berton O., Renthal W., Kumar A., Neve R.L., Nestler E.J. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat. Neurosci. 2006, 9(4):519-525.
111. Tsankova N., Renthal W., Kumar A., Nestler E.J. Epigenetic regulation in psychiatric disorders. Nat. Rev. Neurosci. 2007, 8(5):355-367.
112. Ernst C., Deleva V., Deng X., Sequeira A., Pomarenski A., Klempan T., et al. Alternative splicing, methylation state, and expression profile of tropomyosin-related kinase B in the frontal cortex of suicide completers. Arch. Gen. Psychiatry 2009, 66(1):22-32.
113. Mellios N., Huang H.S., Baker S.P., Galdzicka M., Ginns E., Akbarian S. Molecular determinants of dysregulated GABAergic gene expression in the prefrontal cortex of subjects with schizophrenia. Biol. Psychiatry 2009, 65(12):1006-1014.
114. Roth T.L., Lubin F.D., Funk A.J., Sweatt J.D. Lasting epigenetic influence of early-life adversity on the BDNF gene. Biol. Psychiatry 2009, 65(9):760-769.
115. Keller S., Sarchiapone M., Zarrilli F., Videtic A., Ferraro A., Carli V., et al. Increased BDNF promoter methylation in the Wernicke area of suicide subjects. Arch. Gen. Psychiatry 2010, 67(3):258-267.
116. Fuchikami M., Morinobu S., Segawa M., Okamoto Y., Yamawaki S., Ozaki N., et al. DNA methylation profiles of the brain-derived neurotrophic factor (BDNF) gene as a potent diagnostic biomarker in major depression. PLoS One 2011, 6(8):e23881.
117. D'Addario C., Dell'Osso B., Palazzo M.C., Benatti B., Lietti L., Cattaneo E., et al. Selective DNA methylation of BDNF promoter in bipolar disorder: differences among patients with BDI and BDII. Neuropsychopharmacology 2012, 37(7):1647-1655.
118. Ikegame T., Bundo M., Murata Y., Kasai K., Kato T., Iwamoto K. DNA methylation of the BDNF gene and its relevance to psychiatric disorders. J. Hum. Genet. 2013, 58(7):434-438.
119. Tadic A., Muller-Engling L., Schlicht K.F., Kotsiari A., Dreimuller N., Kleimann A., et al. Methylation of the promoter of brain-derived neurotrophic factor exon IV and antidepressant response in major depression. Mol. Psychiatry 2014, 19(3):281-283.
120. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 2000, 23(5):477-501.
121. Jaaskelainen T., Makkonen H., Palvimo J.J. Steroid up-regulation of FKBP51 and its role in hormone signaling. Curr. Opin. Pharmacol. 2011, 11(4):326-331.
122. Binder E.B., Salyakina D., Lichtner P., Wochnik G.M., Ising M., Putz B., et al. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat. Genet. 2004, 36(12):1319-1325.
123. Kirchheiner J., Lorch R., Lebedeva E., Seeringer A., Roots I., Sasse J., et al. Genetic variants in FKBP5 affecting response to antidepressant drug treatment. Pharmacogenomics 2008, 9(7):841-846.
124. Papiol S., Arias B., Gasto C., Gutierrez B., Catalan R., Fananas L. Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment. J. Affect. Disord. 2007, 104(1-3):83-90.
125. Tsai S.J., Hong C.J., Chen T.J., Yu Y.W. Lack of supporting evidence for a genetic association of the FKBP5 polymorphism and response to antidepressant treatment. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2007, 144B(8):1097-1098.
126. Lekman M., Laje G., Charney D., Rush A.J., Wilson A.F., Sorant A.J., et al. The FKBP5-gene in depression and treatment response-an association study in the sequenced treatment alternatives to relieve depression (STAR*D) cohort. Biol. Psychiatry 2008, 63(12):1103-1110.
127. Zobel A., Schuhmacher A., Jessen F., Hofels S., von Widdern O., Metten M., et al. DNA sequence variants of the FKBP5 gene are associated with unipolar depression. Int. J. Neuropsychopharmacol. 2010, 13(5):649-660.
128. Zou Y.F., Wang F., Feng X.L., Li W.F., Tao J.H., Pan F.M., et al. Meta-analysis of FKBP5 gene polymorphisms association with treatment response in patients with mood disorders. Neurosci. Lett. 2010, 484(1):56-61.
129. Ellsworth K.A., Moon I., Eckloff B.W., Fridley B.L., Jenkins G.D., Batzler A., et al. FKBP5 genetic variation: association with selective serotonin reuptake inhibitor treatment outcomes in major depressive disorder. Pharmacogenet. Genomics 2013, 23(3):156-166.
130. Menke A., Klengel T., Rubel J., Bruckl T., Pfister H., Lucae S., et al. Genetic variation in FKBP5 associated with the extent of stress hormone dysregulation in major depression. Genes Brain Behav. 2013, 12(3):289-296.
131. Szczepankiewicz A., Leszczynska-Rodziewicz A., Pawlak J., Narozna B., Rajewska-Rager A., Wilkosc M., et al. FKBP5 polymorphism is associated with major depression but not with bipolar disorder. J. Affect. Disord. 2014, 164:33-37.
132. Papakostas G.I., Shelton R.C., Kinrys G., Henry M.E., Bakow B.R., Lipkin S.H., et al. Assessment of a multi-assay, serum-based biological diagnostic test for major depressive disorder: a pilot and replication study. Mol. Psychiatry 2013, 18(3):332-339.
133. Schwarz E., Izmailov R., Spain M., Barnes A., Mapes J.P., Guest P.C., et al. Validation of a blood-based laboratory test to aid in the confirmation of a diagnosis of schizophrenia. Biomark. Insights 2010, 5:39-47.
134. Kingsmore S.F. Comment on "validation of a blood-based laboratory test to aid in the confirmation of a diagnosis of schizophrenia". Biomark. Insights 2014, 9:7.
135. Lo L.H., Huang T.L., Shiea J. Acid hydrolysis followed by matrix-assisted laser desorption/ionization mass spectrometry for the rapid diagnosis of serum protein biomarkers in patients with major depression. Rapid Commun. Mass Spectrom. 2009, 23(5):589-598.
136. Huang T.L., Sung M.L., Chen T.Y. 2D-DIGE proteome analysis on the platelet proteins of patients with major depression. Proteome Sci. 2014, 12(1):1.
137. Wilkins M.R., Pasquali C., Appel R.D., Ou K., Golaz O., Sanchez J.C., et al. From proteins to proteomes: large scale protein identification by two-dimensional electrophoresis and amino acid analysis. Biotechnology (N Y) 1996, 14(1):61-65.
138. Martins-de-Souza D., Guest P.C., Harris L.W., Vanattou-Saifoudine N., Webster M.J., Rahmoune H., et al. Identification of proteomic signatures associated with depression and psychotic depression in post-mortem brains from major depression patients. Transl. Psychiatry 2012, 2:e87.
139. Martins-de-Souza D., Harris L.W., Guest P.C., Bahn S. The role of energy metabolism dysfunction and oxidative stress in schizophrenia revealed by proteomics. Antioxid. Redox Signal. 2011, 15(7):2067-2079.
140. Barbier E., Wang J.B. Anti-depressant and anxiolytic like behaviors in PKCI/HINT1 knockout mice associated with elevated plasma corticosterone level. BMC Neurosci. 2009, 10:132.
141. Varadarajulu J., Lebar M., Krishnamoorthy G., Habelt S., Lu J., Bernard Weinstein I., et al. Increased anxiety-related behaviour in Hint1 knockout mice. Behav. Brain Res. 2011, 220(2):305-311.
142. Martins-de-Souza D., Guest P.C., Vanattou-Saifoudine N., Rahmoune H., Bahn S. Phosphoproteomic differences in major depressive disorder postmortem brains indicate effects on synaptic function. Eur. Arch. Psychiatry Clin. Neurosci. 2012, 262(8):657-666.
143. Johnston-Wilson N.L., Sims C.D., Hofmann J.P., Anderson L., Shore A.D., Torrey E.F., et al. Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. The Stanley Neuropathology Consortium. Mol. Psychiatry 2000, 5(2):142-149.
144. Beasley C.L., Pennington K., Behan A., Wait R., Dunn M.J., Cotter D. Proteomic analysis of the anterior cingulate cortex in the major psychiatric disorders: evidence for disease-associated changes. Proteomics 2006, 6(11):3414-3425.
145. Huang J.T., Leweke F.M., Oxley D., Wang L., Harris N., Koethe D., et al. Disease biomarkers in cerebrospinal fluid of patients with first-onset psychosis. PLoS Med. 2006, 3(11):e428.
146. Ditzen C., Tang N., Jastorff A.M., Teplytska L., Yassouridis A., Maccarrone G., et al. Cerebrospinal fluid biomarkers for major depression confirm relevance of associated pathophysiology. Neuropsychopharmacology 2012, 37(4):1013-1025.
147. Xu H.B., Zhang R.F., Luo D., Zhou Y., Wang Y., Fang L., et al. Comparative proteomic analysis of plasma from major depressive patients: identification of proteins associated with lipid metabolism and immunoregulation. Int. J. Neuropsychopharmacol. 2012, 15(10):1413-1425.
148. Stelzhammer V., Haenisch F., Chan M.K., Cooper J.D., Steiner J., Steeb H., et al. Proteomic changes in serum of first onset, antidepressant drug-naive major depression patients. Int. J. Neuropsychopharmacol. 2014, 17(10):1599-1608.
149. Stelzhammer V., Guest P.C., Rothermundt M., Sondermann C., Michael N., Schwarz E., et al. Electroconvulsive therapy exerts mainly acute molecular changes in serum of major depressive disorder patients. Eur. Neuropsychopharmacol. 2013, 23(10):1199-1207.
150. Martins-de-Souza D., Maccarrone G., Ising M., Kloiber S., Lucae S., Holsboer F., et al. Blood mononuclear cell proteome suggests integrin and Ras signaling as critical pathways for antidepressant treatment response. Biol. Psychiatry 2014, 76:e15-e17.
151. Breitenstein B., Scheuer S., Holsboer F. Are there meaningful biomarkers of treatment response for depression?. Drug Discov. Today 2014, 19:539-561.
152. Kaddurah-Daouk R., Krishnan K.R. Metabolomics: a global biochemical approach to the study of central nervous system diseases. Neuropsychopharmacology 2009, 34(1):173-186.
153. Kaddurah-Daouk R., Yuan P., Boyle S.H., Matson W., Wang Z., Zeng Z.B., et al. Cerebrospinal fluid metabolome in mood disorders-remission state has a unique metabolic profile. Sci. Rep. 2012, 2:667.
154. Paige L.A., Mitchell M.W., Krishnan K.R., Kaddurah-Daouk R., Steffens D.C. A preliminary metabolomic analysis of older adults with and without depression. Int. J. Geriatr. Psychiatry 2007, 22(5):418-423.
155. Steffens D.C., Wei J., Krishnan K.R., Karoly E.D., Mitchell M.W., O'Connor C.M., et al. Metabolomic differences in heart failure patients with and without major depression. J. Geriatr. Psychiatry Neurol. 2010, 23(2):138-146.
156. Zheng P., Gao H.C., Li Q., Shao W.H., Zhang M.L., Cheng K., et al. Plasma metabonomics as a novel diagnostic approach for major depressive disorder. J. Proteome Res. 2012, 11(3):1741-1748.
157. Kaddurah-Daouk R., Boyle S.H., Matson W., Sharma S., Matson S., Zhu H., et al. Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept. Transl. Psychiatry 2011, 1:e26.
158. Kaddurah-Daouk R., Bogdanov M.B., Wikoff W.R., Zhu H., Boyle S.H., Churchill E., et al. Pharmacometabolomic mapping of early biochemical changes induced by sertraline and placebo. Transl. Psychiatry 2013, 3:e223.
159. Zhu H., Bogdanov M.B., Boyle S.H., Matson W., Sharma S., Matson S., et al. Pharmacometabolomics of response to sertraline and to placebo in major depressive disorder-possible role for methoxyindole pathway. PLoS One 2013, 8(7):e68283.
160. Ding X., Yang S., Li W., Liu Y., Li Z., Zhang Y., et al. The potential biomarker panels for identification of major depressive disorder (MDD) patients with and without early life stress (ELS) by metabonomic analysis. PLoS One 2014, 9(5):e97479.
161. Zheng P., Wang Y., Chen L., Yang D., Meng H., Zhou D., et al. Identification and validation of urinary metabolite biomarkers for major depressive disorder. Mol. Cell. Proteomics 2013, 12(1):207-214.
162. Coulombe B. Mapping the disease protein interactome: toward a molecular medicine GPS to accelerate drug and biomarker discovery. J. Proteome Res. 2011, 10(1):120-125.
163. Chen J., Zhou J., Sanders C.K., Nolan J.P., Cai H. A surface display yeast two-hybrid screening system for high-throughput protein interactome mapping. Anal. Biochem. 2009, 390(1):29-37.
164. Scifo E., Szwajda A., Debski J., Uusi-Rauva K., Kesti T., Dadlez M., et al. Drafting the CLN3 protein interactome in SH-SY5Y human neuroblastoma cells: a label-free quantitative proteomics approach. J. Proteome Res. 2013, 12(5):2101-2115.
165. Bonfiglio J.J., Maccarrone G., Rewerts C., Holsboer F., Arzt E., Turck C.W., et al. Characterization of the B-Raf interactome in mouse hippocampal neuronal cells. J. Proteomics 2011, 74(2):186-198.
166. Weichhart T., Saemann M.D. The PI3K/Akt/mTOR pathway in innate immune cells: emerging therapeutic applications. Ann. Rheum. Dis. 2008, 67(Suppl. 3):iii70-iii74.
167. Pilot-Storck F., Chopin E., Rual J.F., Baudot A., Dobrokhotov P., Robinson-Rechavi M., et al. Interactome mapping of the phosphatidylinositol 3-kinase-mammalian target of rapamycin pathway identifies deformed epidermal autoregulatory factor-1 as a new glycogen synthase kinase-3 interactor. Mol. Cell. Proteomics 2010, 9(7):1578-1593.
168. Jia P., Kao C.F., Kuo P.H., Zhao Z. A comprehensive network and pathway analysis of candidate genes in major depressive disorder. BMC Syst. Biol. 2011, 5(Suppl. 3):S12.
169. Franceschini A., Szklarczyk D., Frankild S., Kuhn M., Simonovic M., Roth A., et al. STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res. 2013, 41(Database issue):D808-D815.
170. Huang C.E., Huang T.L. Intramuscular lorazepam in catatonia in patients with acute renal failure: a report of two cases. Chang Gung Med. J. 2010, 33(1):106-109.
171. Huang Y.C., Lin C.C., Hung Y.Y., Huang T.L. Rapid relief of catatonia in mood disorder by lorazepam and diazepam. Biomed. J. 2013, 36(1):35-39.